Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Free Cash Flow (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Free Cash Flow for 7 consecutive years, with -$264000.0 as the latest value for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 84.62% year-over-year to -$264000.0; the TTM value through Sep 2025 reached -$1.4 million, up 77.94%, while the annual FY2024 figure was -$4.3 million, 79.6% up from the prior year.
  • Free Cash Flow hit -$264000.0 in Q3 2025 for Cyclerion Therapeutics, up from -$503000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $360000.0 in Q4 2024 and bottomed at -$14.5 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$5.5 million, with a median of -$6.2 million recorded in 2023.
  • Year-over-year, Free Cash Flow crashed 96.37% in 2022 and then soared 123.36% in 2024.
  • Cyclerion Therapeutics' Free Cash Flow stood at -$8.6 million in 2021, then increased by 18.39% to -$7.0 million in 2022, then skyrocketed by 78.12% to -$1.5 million in 2023, then skyrocketed by 123.36% to $360000.0 in 2024, then plummeted by 173.33% to -$264000.0 in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$264000.0, -$503000.0, and -$968000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.